Zobrazeno 21 - 30
of 69
pro vyhledávání: '"Fabrice Andre"'
Autor:
Charles Coutant, Agnès Dumas, Laurence Vanlemmens, Suzette Delaloge, Christelle Mesleard, Olivier Tredan, Gwenn Menvielle, Sandrine Pinto, Paul Cottu, Mayssam El Mouhebb, Jérôme Lemonnier, Cécile Charles, Thomas Bovagnet, A. Lesur, Sarah Dauchy, Fabrice Andre, Antonio Di Meglio, Patrick Arveux, Christelle Levy, Ines Maria Vaz Duarte Luis, Florence Lerebours
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2020, 38 (7), pp.734-743. ⟨10.1200/jco.19.01726⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2020, 38 (7), pp.734-743. ⟨10.1200/jco.19.01726⟩
PURPOSE Adverse effects of breast cancer treatment can negatively affect survivors’ work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f8e9248494ef063680decfa22c4ba9d
https://hal.archives-ouvertes.fr/hal-03088680
https://hal.archives-ouvertes.fr/hal-03088680
Autor:
Maud Ngo-Camus, Jeanne Chen, Anas Gazzah, Etienne Rouleau, Cécile Jovelet, David Planchard, Luc Friboulet, Gilles Vassal, Diego Enrico, Jordi Remon, Ludovic Lacroix, Stefan Michiels, Laura Mezquita, Christophe Massard, Gonzalo Recondo, Jean-Charles Soria, Jean-Yves Scoazec, Fabrice Andre, Benjamin Besse, Francesco Facchinetti, Yohann Loriot, Lambros Tselikas
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100023-(2020)
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100023-(2020)
Introduction Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic kinase fusions
Autor:
Florent Ginhoux, Agathe Dubuisson, Bertrand Gachot, Aymeric Silvin, Aurélien Marabelle, Imran Lahmar, Mauro Piacentini, Cléa Melenotte, Laurence Zitvogel, Guido Kroemer, Clémence Hénon, Lisa Derosa, Eric Solary, Michaela Fontenay, Didier Raoult, Fu-Sheng Wang, Markus Maeurer, Giuseppe Ippolito, Alimuddin Zumla, Mansouria Merad, Anne Gaëlle Goubet, Fabrice Andre
Publikováno v:
OncoImmunology
OncoImmunology, 2020, 9 (1), pp.1807836. ⟨10.1080/2162402X.2020.1807836⟩
OncoImmunology, Taylor & Francis, 2020, 9 (1), pp.1807836. ⟨10.1080/2162402X.2020.1807836⟩
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, 2020, 9 (1), pp.1807836. ⟨10.1080/2162402X.2020.1807836⟩
OncoImmunology, Taylor & Francis, 2020, 9 (1), pp.1807836. ⟨10.1080/2162402X.2020.1807836⟩
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6b3330afafb3e68f7e7025c65974ed7
https://doi.org/10.1080/2162402X.2020.1807836
https://doi.org/10.1080/2162402X.2020.1807836
Autor:
Lambros Tselikas, Eric Angevin, Antoine Hollebecque, Jean-Yves Scoazec, Francesco Facchinetti, Aline Maillard, Maud Ngo-Camus, C. Naltet, Ken A. Olaussen, Anas Gazzah, Stefan Michiels, Fabrice Andre, Thierry de Baere, Ludovic Bigot, David Planchard, Gilles Vassal, Ludovic Lacroix, Eric Solary, Catherine Richon, Luc Friboulet, Olivier Deas, Benjamin Besse, Linda Mahjoubi, Claudio Nicotra, Rastislav Bahleda, Yohann Loriot, Rosa L. Frias, Pernelle Lavaud, Aurelie Abou Lovergne, Gonzalo Recondo, Laura Mezquita, Christophe Massard, Jean-Charles Soria, Alexander M.M. Eggermont
Publikováno v:
NPJ Precision Oncology
npj Precision Oncology
npj Precision Oncology, Vol 4, Iss 1, Pp 1-8 (2020)
npj Precision Oncology
npj Precision Oncology, Vol 4, Iss 1, Pp 1-8 (2020)
Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary ob
Autor:
Magali Lacroix-Triki, Clara Nahmias, Jean-Yves Pierga, Elisabetta Marangoni, Marie-Eglantine Dujaric, Patricia de Cremoux, Nicolas Servant, Bernard Asselain, Fabrice Andre, Cynthia Seiler, Monica Arnedos, Sylvie Rodrigues-Ferreira, Clarisse Monchecourt, Sophie Chateau-Joubert, Hadia Moindjie, Anne Nehlig
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2019, 116 (47), pp.23691-23697. ⟨10.1073/pnas.1910824116⟩
Proc Natl Acad Sci U S A
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116 (47), pp.23691-23697. ⟨10.1073/pnas.1910824116⟩
Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2019, 116 (47), pp.23691-23697. ⟨10.1073/pnas.1910824116⟩
Proc Natl Acad Sci U S A
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116 (47), pp.23691-23697. ⟨10.1073/pnas.1910824116⟩
International audience; Predictive biomarkers for tumor response to neoadjuvant chemotherapy are needed in breast cancer. This study investigates the predictive value of 280 genes encoding proteins that regulate microtubule assembly and function. By
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baca692b7dbb1befa05d67809af1e229
https://hal-univ-tlse2.archives-ouvertes.fr/hal-02411561/document
https://hal-univ-tlse2.archives-ouvertes.fr/hal-02411561/document
Autor:
Charles L. Sawyers, Emile E. Voest, Jeremy Lewin, Lillian L. Siu, Robyn L. Ward, Mark Lawler, Anamaria A. Camargo, Mao Mao, L. F. A. Wessels, Rachel G. Liao, Fabien Calvo, Fabrice Andre, Bartha Maria Knoppers, Bin Tean Teh, Daniel J. Vis
Publikováno v:
Vis, D J, Lewin, J, Liao, R G, Mao, M, Andre, F, Ward, R L, Calvo, F, Teh, B T, Camargo, A A, Knoppers, B M, Sawyers, C L, Wessels, L F A, Lawler, M, Siu, L L, Voest, E & Clinical Working Group of the Global Alliance for Genomics and Health 2017, ' Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape ' Annals of Oncology, vol. 28, no. 5, pp. 1145-1151 . DOI: 10.1093/annonc/mdx037
Annals of Oncology
Annals of Oncology
Background: While next generation sequencing has enhanced our understanding of the biological basis of malignancy, current knowledge on global practices for sequencing cancer samples is limited. To address this deficiency, we developed a survey to pr
Autor:
Alexandra Jacquet, Alicia Tran Dien, Guillaume Meurice, Marta Jimenez, Charlotte K.Y. Ng, Salvatore Piscuoglio, Semih Dogan, Yahia Adnani, Christophe Le Tourneau, Mario Campone, Jean-Charles Soria, Maud Kamal, Max Chaffanet, Thomas Filleron, François Bertucci, Thomas Bachelot, Nadine Carbuccia, Maria R. De Filippo, Anne Patsouris, Claudia Lefeuvre, Daniel Birnbaum, Florence Dalenc, Naveen Babbar, Benjamin Verret, Nathalie Droin, Séverine Garnier, Hervé Bonnefoi, Fabrice Andre
Publikováno v:
Nature
Nature, 2019, 572 (7767), pp.E7-E7. ⟨10.1038/s41586-019-1380-3⟩
Nature, Nature Publishing Group, 2019, 572 (7767), pp.E7-E7. ⟨10.1038/s41586-019-1380-3⟩
Nature, 2019, 572 (7767), pp.E7-E7. ⟨10.1038/s41586-019-1380-3⟩
Nature, Nature Publishing Group, 2019, 572 (7767), pp.E7-E7. ⟨10.1038/s41586-019-1380-3⟩
International audience; An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d85b0fb8561e5c1fb5c00b3912e2b57
https://hal.science/hal-02504834
https://hal.science/hal-02504834
Autor:
Olivier Tredan, Johan Adnet, Fabrice Andre, Paul Cottu, Ines Vaz-Luis, Christel Mesleard, Sarah Dauchy, Patrick Arveux, Christelle Levy, Marina Rousseau Tsangaris, Anne Laure Martin, Agnès Dumas
Publikováno v:
ESMO Open
ESMO Open, Vol 4, Iss 5 (2019)
ESMO Open, Vol 4, Iss 5 (2019)
Background Corresponding with improved survival among patients with breast cancer, the awareness of the long-term effects of cancer treatments has increased. CANcer TOxicities (CANTO) aims to identify predictors of development and persistence of long
Autor:
Alexandra Jacquet, Alicia Tran Dien, Thomas Bachelot, Mario Campone, Fabrice Andre, Claudia Lefeuvre, Guillaume Meurice, Salvatore Piscuoglio, Yahia Adnani, Daniel Birnbaum, Florence Dalenc, Hervé Bonnefoi, Maud Kamal, Marta Jimenez, François Bertucci, Max Chaffanet, Charlotte K.Y. Ng, Benjamin Verret, Nadine Carbuccia, Anne Patsouris, Christophe Le Tourneau, Naveen Babbar, Maria R. De Filippo, Thomas Filleron, Semih Dogan, Nathalie Droin, Jean-Charles Soria, Séverine Garnier
Publikováno v:
Nature
Nature, 2019, 569 (7757), pp.560-564. ⟨10.1038/s41586-019-1056-z⟩
Nature, Nature Publishing Group, 2019, 569 (7757), pp.560-564. ⟨10.1038/s41586-019-1056-z⟩
Nature, 2019, 569 (7757), pp.560-564. ⟨10.1038/s41586-019-1056-z⟩
Nature, Nature Publishing Group, 2019, 569 (7757), pp.560-564. ⟨10.1038/s41586-019-1056-z⟩
International audience; Metastasis is the main cause of death for patients with breast cancer. Many studies have characterized the genomic landscape of breast cancer during its early stages. However, there is evidence that genomic alterations are acq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f10317699779eb2af91297159ff87964
https://hal.archives-ouvertes.fr/hal-02504838
https://hal.archives-ouvertes.fr/hal-02504838
Autor:
Jean-Yves Scoazec, Jean-Charles Soria, Gonzalo Recondo, Aurelie Abou Lovergne, Gilles Vassal, Tony Sourisseau, Pernelle Lavaud, Justine Galissant, Nathalie Auger, Antoine Hollebecque, Laura Mezquita, Alexander M.M. Eggermont, Maud Ngo-Camus, Karen Howarth, Christophe Massard, Rastilav Bahleda, David Planchard, Rosa L. Frias, Lambros Tselikas, Anas Gazzah, Fabrice Andre, Eric Angevin, Stefan Michiels, Floriane Braye, Luc Friboulet, Ken A. Olaussen, Ahsan Z. Rizvi, Linda Mahjoubi, Ludovic Bigot, Claudio Nicotra, Francesco Facchinetti, C. Naltet, Pauline Tesson, Ludovic Lacroix, D. O. Samofalova, Benjamin Besse, Eric Solary, Catherine Richon, Thierry de Baere, Jean Paul Thiery, Olivier Deas
Publikováno v:
Clin Cancer Res
Clinical Cancer Research
Clinical Cancer Research
Purpose:Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound